News blog

Policy paper: Myriad turns cancer genetic data into trade secrets

If the information Myriad Genetics has collected about breast cancer mutations remains proprietary, costs of gene tests could increase while quality declines, argues Robert Cook-Deegan, a policy researcher at Duke University in Durham, North Carolina. In a paper published today in the European Journal of Human Genetics, Cook-Deegan and co-authors John Conley, James Evans, and Daniel Vorhaus urge health-care payers and policy makers to encourage the company to share clinical data and proprietary algorithms. 


Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.